id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-N-0196-0020,FDA,FDA-2003-N-0196,Response from FDA/CDER to Buchanan Ingersoll,Other,Answer,2003-12-15T05:00:00Z,2003,12,,,2014-06-09T21:16:55Z,,0,0,090000648048b603
FDA-2003-N-0196-0021,FDA,FDA-2003-N-0196,"Response from FDA/CDER to North America Cosmetic Division, Symrise",Other,Answer,2003-12-15T05:00:00Z,2003,12,,,2014-06-09T21:22:06Z,,0,0,090000648048b618
FDA-2003-N-0196-0022,FDA,FDA-2003-N-0196,"Response from FDA/CDER to Morgan, Lewis & Bockius LLP",Other,Answer,2003-12-15T05:00:00Z,2003,12,,,2014-06-09T21:33:27Z,,0,0,090000648048b61e
FDA-2003-N-0196-0013,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:20Z,,0,0,090000648048b587
FDA-2003-N-0196-0007,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:20Z,,0,0,090000648048b56c
FDA-2003-N-0196-0016,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:20Z,,0,0,090000648048b596
FDA-2003-N-0196-0008,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:20Z,,0,0,090000648048b571
FDA-2003-N-0196-0002,FDA,FDA-2003-N-0196,"Division of OTC Drug Products Memorandum to Dockets Management, July 14, 2003 - ""Public Admlnistratlve File for Over-the-Counter Drug Products; Safety and Efficacy, Volume No. 352-01"" - Background",Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2014-06-09T20:51:58Z,,0,0,090000648048b53d
FDA-2003-N-0196-0003,FDA,FDA-2003-N-0196,"Reference 5  FDA's Evaluation and Comments on the TEA for Encacamene Division of OTC Drug Products Memorandum to Dockets Management, July 14, 2003 re Public Admlnistratlve File for Over-the-Counter Drug Products; Safety and Efficacy, Volume No. 352-01 - Background",Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2014-06-09T20:52:46Z,,0,0,090000648048b554
FDA-2003-N-0196-0009,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:20Z,,0,0,090000648048b577
FDA-2003-N-0196-0005,FDA,FDA-2003-N-0196,"Regulatory Review - (Ego Pharmaceuticals, Pty Ltd. - Data and Information)]",Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2010-07-16T16:03:27Z,,0,0,090000648048b561
FDA-2003-N-0196-0014,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:21Z,,0,0,090000648048b58b
FDA-2003-N-0196-0019,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:21Z,,0,0,090000648048b5a1
FDA-2003-N-0196-0004,FDA,FDA-2003-N-0196,"Table of Contents Time and Extent Application for Amiloxate - [Amiloxate, Neo Heliopan® 1000"" - (Ego Pharmaceuticals, Pty Ltd. - Data and Information)]",Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2010-07-16T16:00:52Z,,0,0,090000648048b559
FDA-2003-N-0196-0010,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:21Z,,0,0,090000648048b57a
FDA-2003-N-0196-0017,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:21Z,,0,0,090000648048b599
FDA-2003-N-0196-0011,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:20Z,,0,0,090000648048b580
FDA-2003-N-0196-0006,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:21Z,,0,0,090000648048b568
FDA-2003-N-0196-0015,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:21Z,,0,0,090000648048b592
FDA-2003-N-0196-0018,FDA,FDA-2003-N-0196,"Reference 6 - ""FDA's Evaluation and Comments on the TEA for Octyl Trlazone."" - [Division of OTC Drug Products Memorandum to Dockets Management, July 14, 2003 - ""Public Admlnistratlve File for Over-the-Counter Drug Products; Safety and Efficacy, Volume No. 352-01"" - Background]",Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2014-06-09T20:54:14Z,,0,0,090000648048b59e
FDA-2003-N-0196-0012,FDA,FDA-2003-N-0196,BACKGROUND,Supporting & Related Material,BKG-Background Material,2003-07-30T04:00:00Z,2003,7,,,2008-04-12T00:59:20Z,,0,0,090000648048b583
FDA-2003-N-0196-0001,FDA,FDA-2003-N-0196,Over-the-Counter Drug Products; Safety and Efficacy Review; Additional Sunscreen Ingredients,Notice,Requests for Information (RFI),2003-07-11T04:00:00Z,2003,7,2003-07-11T04:00:00Z,2003-10-11T03:59:59Z,2014-06-14T20:55:15Z,,0,0,090000648048b511